Attila Seyhan named Fox Chase director of translational medicine operations

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Attila Seyhan was named director of translational medicine operations, a newly created position, at Fox Chase Cancer Center.

Seyhan will work closely with Wafik S. El-Deiry, deputy cancer center director for translational research, to manage and promote multiple initiatives, including development of investigator-initiated clinical trials and other translational protocols, protocol writing and manuscript preparation, organization of translational medicine events, support for translational requests for application, and grant preparation and submissions.

He also will work with industry to follow through on investigator-initiated basic and translational letters of intent and concepts. This work will involve collaboration with clinicians, scientists, regulatory personnel, administrators, tech transfer office staff, the grants management office, institutional review board, institutional advancement, and external entities.

A molecular biologist, Seyhan has more than 16 years of experience in drug, target, and biomarker discovery and development, as well as preclinical and clinical translational research, focused on diabetes and metabolic diseases, cancer, inflammation and immunology, molecular virology, and rare genetic diseases.

His most recent position was associate professor at the Translational Research Institute for Metabolism and Diabetes at Florida Hospital in Orlando, FL, and adjunct associate professor at Sanford Burnham Prebys Medical Discovery Institute, in Orlando. In addition, he served as a research affiliate in the department of chemical engineering at Massachusetts Institute of Technology.

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login